This site provides INTERCEPT product information for Health Care Professionals in the United States.

Webinars and Podcasts

Back to resources

Optimizing Fibrinogen Replacement: IFC in Trauma

Timely administration of fibrinogen and other key clotting
factors is essential to treating coagulopathy associated with
fibrinogen deficiency. Access to fibrinogen sources (such as
cryo AHF and fibrinogen concentrates) can be challenging
given their long wait times, need to reconstitute, cost,
wastage and short shelf life. Join us to learn how INTERCEPT®
Fibrinogen Complex (IFC) is immediately available* due
to its 5-day post thaw shelf life, improving patient access
to fibrinogen supplementation during hemorrhage. Hear
experts in OB, CV & trauma anesthesia speak to their IFC
experiences and how it impacts their patient care.

Roman Dudaryk, MD
Professor of Anesthesiology
Division of Trauma Anesthesia/Critical Care Medicine
University of Miami / Jackson Memorial Hospital

Dr. Roman Dudaryk is a Professor of Anesthesiology and serves as the Director of Quality in the Department of Anesthesiology, Perioperative Medicine, and Pain Management at the University of Miami Miller School of Medicine. He plays a leading role in trauma and critical care at Ryder Trauma Center at Jackson Memorial Hospital, one of the nation’s premier trauma centers, where he contributes to advancing the care of critically injured patients. Dr. Dudaryk completed his residency in anesthesiology at Jackson Memorial Hospital, where he served as chief resident. He then pursued a fellowship in critical care medicine and perioperative echocardiography at Duke University. He is board-certified in anesthesiology, critical care medicine, and perioperative transesophageal echocardiography. Dr. Dudaryk has authored over 50 peer-reviewed publications, including original research manuscripts, invited editorials, review articles, and book chapters. His research interests focus on trauma-induced coagulopathy, resuscitation, transfusion strategies, viscoelastic monitoring, perioperative anticoagulation management, and medical alarms. He has presented his research at national and international conferences and is a frequent lecturer on topics within his expertise.

* INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use.

MKT-EN 00888 v1.0
MKT-EN 00889 v1.0

Watch the Replay
Runtime: 20 min

INTERCEPT® Blood System for Platelets Pathogen Reduction System

INTENDED USE

The INTERCEPT Blood System for Platelets is intended to be used for ex vivo preparation of pathogen-reduced Amicus apheresis platelet components suspended in 65% PAS-3/35% plasma, and Trima apheresis platelet components suspended in 100% plasma in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD).

CONTRAINDICATIONS

Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process.

Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex

INTENDED USE
The INTERCEPT Blood System for Cryoprecipitation is intended to provide a functionally closed system for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

Pathogen Reduced Cryoprecipitated Fibrinogen Complex is indicated for:

Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
Second-line therapy for von Willebrand disease (vWD).
Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: Should not be used for replacement of factor VIII.

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.